Edition:
United Kingdom

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

89.94EUR
15 Aug 2018
Change (% chg)

€-0.82 (-0.90%)
Prev Close
€90.76
Open
€90.80
Day's High
€91.56
Day's Low
€89.62
Volume
402,251
Avg. Vol
425,044
52-wk High
€98.82
52-wk Low
€70.64

Chart for

About

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services... (more)

Overall

Beta: 1.05
Market Cap(Mil.): €4,412.26
Shares Outstanding(Mil.): 50.87
Dividend: --
Yield (%): --

Financials

  GLPG.AS Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.58 -- --
ROI: -2.51 1.78 14.61
ROE: -3.05 3.28 16.33

BRIEF-Galapagos NV reports H1 Group Revenues Of €101.9 Million

* CASH AND CASH EQUIVALENTS ON 30 JUNE 2018 OF €1,066.8 MILLION

02 Aug 2018

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

ZURICH Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

19 Jul 2018

Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug

ZURICH, July 19 Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

19 Jul 2018

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES

21 Jun 2018

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

01 May 2018

BRIEF-Galapagos Presents Strong Disease-Modifying Effects With Glpg1972 At Oarsi 2018

* REG-GALAPAGOS PRESENTS STRONG DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODEL OF OSTEOARTHRITIS WITH GLPG1972 AT OARSI 2018

27 Apr 2018

BRIEF-Galapagos Q1 Operating Loss Widens To 32.0 Million Euros

* Q1 REVENUE EUR 44.8 MILLION VERSUS EUR 39.9 MILLION YEAR AGO

25 Apr 2018

BRIEF-Galapagos NV Q1 Basic And Diluted Loss Per Share EUR 0.73

* GALAPAGOS EXPECTS AN OPERATIONAL CASH BURN BETWEEN €220 AND €240 MILLION IN 2018

25 Apr 2018

BRIEF-Galapagos NV Creates New Warrant Plan

* BOARD OF DIRECTORS CREATED 1.6 MILLION WARRANTS UNDER NEW WARRANT PLANS

19 Apr 2018

BRIEF-Galapagos Announces ISABELA Phase 3 Program In IPF

* ANNOUNCES THE DESIGN OF A WORLDWIDE PHASE 3 PROGRAM, TO EVALUATE GLPG1690 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

12 Apr 2018

Earnings vs. Estimates